Riferimento:
Clin Exp Nephrol. 2011 Jun;15(3):434-7.
Autori:
Tsuchiya Y, Ubara Y, Suwabe T, Hoshino J, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Marui Y, Sawa N, Takemoto F, Takaichi K. yoshiki1209@gmail.com
Fonte:
Clin Exp Nephrol. 2011 Jun;15(3):434-7.
Anno:
2011
Azione:
Acido all-trans retinoico (ATRA) e chemioterapia possono essere tranquillamente somministrati a pazienti con leucemia promielocitica acuta in emodialisi.
Target:
ATRA/leucemia promielocitica acuta.
Acute promyelocytic leukemia (APL) has the best prognosis among acute leukemias, but there is little data about APL in patients on hemodialysis. A 64-year-old hemodialysis patient was successfully treated for APL by induction therapy with all-trans retinoic acid (ATRA), three courses of consolidation therapy with Ara-C, mitomycin C (MIT), daunorubicin (DNR), and idarubicin (IDR), and maintenance therapy with ATRA. Complete remission has been maintained for 42 months in this patient. With dose modification, ATRA and chemotherapy may be safely given to patients on hemodialysis.
Sostanze: